Quantbot Technologies LP Buys 22,987 Shares of Cencora, Inc. (NYSE:COR)

Quantbot Technologies LP boosted its stake in Cencora, Inc. (NYSE:COR) by 39.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,560 shares of the company’s stock after acquiring an additional 22,987 shares during the quarter. Cencora comprises about 0.9% of Quantbot Technologies LP’s holdings, making the stock its largest holding. Quantbot Technologies LP’s holdings in Cencora were worth $18,375,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of COR. Rise Advisors LLC acquired a new stake in shares of Cencora during the first quarter valued at about $25,000. Legacy Bridge LLC purchased a new position in Cencora in the first quarter valued at about $27,000. New Millennium Group LLC acquired a new stake in Cencora during the 2nd quarter valued at approximately $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora in the 1st quarter valued at approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new position in shares of Cencora in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 in the last quarter. Company insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on COR shares. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Wells Fargo & Company increased their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $258.13.

Cencora Stock Performance

Shares of COR stock opened at $239.88 on Monday. The company has a market cap of $47.84 billion, a P/E ratio of 26.25, a PEG ratio of 1.55 and a beta of 0.44. The business has a 50 day moving average of $233.92 and a two-hundred day moving average of $233.24. Cencora, Inc. has a 52 week low of $175.50 and a 52 week high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.92 EPS. As a group, analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. Cencora’s dividend payout ratio is currently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.